PE20221447A1 - Anticuerpos anti-tgf-beta 1 latente y metodos de uso - Google Patents

Anticuerpos anti-tgf-beta 1 latente y metodos de uso

Info

Publication number
PE20221447A1
PE20221447A1 PE2022000303A PE2022000303A PE20221447A1 PE 20221447 A1 PE20221447 A1 PE 20221447A1 PE 2022000303 A PE2022000303 A PE 2022000303A PE 2022000303 A PE2022000303 A PE 2022000303A PE 20221447 A1 PE20221447 A1 PE 20221447A1
Authority
PE
Peru
Prior art keywords
hvr
tgf
latent
beta
antibody
Prior art date
Application number
PE2022000303A
Other languages
English (en)
Inventor
Hideak Shimada
Masakazu Kanamori
Xing'er Christine Koo
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20221447A1 publication Critical patent/PE20221447A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La invencion esta referida a un anticuerpo anti-TGF-beta 1 latente entre especies, humanizados y optimizados, que inhiben una activacion mediada por peptidasa de TGF-beta 1 latente sin inhibir la activacion mediada por integrina de TGF-beta 1 latente; dicho anticuerpo comprende: a) HVR-H1, HVR-H2 y HVR-H3 que comprenden las secuencias de aminoacidos de las SEQ ID no: 20, 21 y 22, respectivamente y HVR-L1, HVR-L2 y HVR-L3 que comprenden las secuencias de aminoacidos de las SEQ ID no: 23, 24 y 25, respectivamente; b) HVR-H1, HVR-H2 y HVR-H3 que comprenden las secuencias de aminoacidos de las SEQ ID no: 26, 27 y 28, respectivamente y HVR-L1, HVR-L2 y HVR-L3 que comprenden las secuencias de aminoacidos de las SEQ ID no: 29, 30 y 31, respectivamente; entre otros. Tambien refiere a un inmunoconjugado que comprende el citado anticuerpo anti-TGF beta1 latente y un agente citotoxico; un acido nucleico aislado que codifica el anticuerpo anti-TGF beta 1 latente; un vector que comprende el acido nucleico; una celula hospedadora; un metodo para producir un anticuerpo anti-TGF-beta1 latente; y una formulacion farmaceutica que comprende dicho anticuerpo.
PE2022000303A 2019-08-28 2020-08-28 Anticuerpos anti-tgf-beta 1 latente y metodos de uso PE20221447A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019155278 2019-08-28
PCT/JP2020/032522 WO2021039945A1 (en) 2019-08-28 2020-08-28 Cross-species anti-latent tgf-beta 1 antibodies and methods of use

Publications (1)

Publication Number Publication Date
PE20221447A1 true PE20221447A1 (es) 2022-09-21

Family

ID=74684250

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000303A PE20221447A1 (es) 2019-08-28 2020-08-28 Anticuerpos anti-tgf-beta 1 latente y metodos de uso

Country Status (18)

Country Link
US (2) US11312767B2 (es)
EP (1) EP4021498A4 (es)
JP (2) JP6846564B2 (es)
KR (2) KR20220043930A (es)
CN (1) CN114729370A (es)
AR (1) AR120077A1 (es)
AU (1) AU2020340176A1 (es)
BR (1) BR112022003412A2 (es)
CA (1) CA3149151A1 (es)
CL (1) CL2022000438A1 (es)
CO (1) CO2022001789A2 (es)
CR (1) CR20220125A (es)
IL (1) IL290816A (es)
MX (1) MX2022001938A (es)
PE (1) PE20221447A1 (es)
SG (1) SG11202009970VA (es)
TW (2) TWI737469B (es)
WO (1) WO2021039945A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220043930A (ko) 2019-08-28 2022-04-05 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005105144A1 (ja) 2004-04-30 2007-09-13 協和醗酵工業株式会社 潜在型ＴＧＦ−βの活性化抑制剤
WO2011102483A1 (ja) 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
JP2016500704A (ja) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 細胞シグナル伝達を変調するための組成物及び方法
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
MX2018003196A (es) * 2015-09-15 2019-05-16 Scholar Rock Inc Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
SG11201807176XA (en) * 2016-03-11 2018-09-27 Scholar Rock Inc TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
AU2018205231A1 (en) 2017-01-06 2019-07-18 Scholar Rock, Inc. Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
JP2020186172A (ja) 2017-06-19 2020-11-19 株式会社ボナック 抗ＴＧＦ−β１抗体
CA3071427A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3755723A4 (en) * 2018-02-23 2021-12-22 Chugai Seiyaku Kabushiki Kaisha CROSS SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
SG11202013231SA (en) 2018-07-11 2021-01-28 Scholar Rock Inc HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
WO2020160291A2 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
KR20220043930A (ko) 2019-08-28 2022-04-05 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
WO2022180764A1 (en) * 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies

Also Published As

Publication number Publication date
CA3149151A1 (en) 2021-03-04
KR102376605B1 (ko) 2022-03-21
AR120077A1 (es) 2022-02-02
IL290816A (en) 2022-04-01
TW202142571A (zh) 2021-11-16
CN114729370A (zh) 2022-07-08
BR112022003412A2 (pt) 2022-05-24
MX2022001938A (es) 2022-03-11
EP4021498A1 (en) 2022-07-06
TW202122422A (zh) 2021-06-16
US20220204605A1 (en) 2022-06-30
EP4021498A4 (en) 2024-01-03
KR20210039328A (ko) 2021-04-09
CL2022000438A1 (es) 2022-11-25
TWI737469B (zh) 2021-08-21
JP6846564B2 (ja) 2021-03-24
CR20220125A (es) 2022-05-04
AU2020340176A1 (en) 2022-04-14
US20210395356A1 (en) 2021-12-23
CO2022001789A2 (es) 2022-06-10
JP2021118685A (ja) 2021-08-12
US11312767B2 (en) 2022-04-26
WO2021039945A1 (en) 2021-03-04
JP2021036864A (ja) 2021-03-11
KR20220043930A (ko) 2022-04-05
SG11202009970VA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
PE20221447A1 (es) Anticuerpos anti-tgf-beta 1 latente y metodos de uso
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
JP2020500538A5 (es)
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
JP2018521638A5 (es)
PE20240365A1 (es) Anticuerpos anti-c5 y metodos de uso
JP2016511277A5 (es)
PE20180317A1 (es) Anticuerpos anti-tau y metodos de uso
HRP20231196T1 (hr) Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
JP2015533795A5 (es)
RU2017119543A (ru) Анти-tim3 антитела и способы их применения
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
AR114281A1 (es) Anticuerpos anti-klk5 y métodos de uso
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
PE20191548A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
JP2016503413A5 (es)
PE20181009A1 (es) ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
NZ626520A (en) Anti-lrp5 antibodies and methods of use
PE20220487A1 (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos
PE20211605A1 (es) ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS